Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use IMLYGIC safely and effectively. See full prescribing information for IMLYGIC . I MLYGIC® ( talimogene laherparepvec ) Suspension for intralesional injection Initial U.S. Approval: 2015
Medication labelWhy this: Advisory · dailymed-prescription
IMLYGIC is a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery. Limitations of use: IMLYGIC has not been shown to improve overall survival or have an effect on visceral metastases.
- generic_name
- talimogene laherparepvec
- product_names
- talimogene laherparepvec
- ndc
- 55513-078, 55513-079, 55513-078-01, 55513-079-01
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en